EA023344B1 - Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией - Google Patents
Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией Download PDFInfo
- Publication number
- EA023344B1 EA023344B1 EA201190080A EA201190080A EA023344B1 EA 023344 B1 EA023344 B1 EA 023344B1 EA 201190080 A EA201190080 A EA 201190080A EA 201190080 A EA201190080 A EA 201190080A EA 023344 B1 EA023344 B1 EA 023344B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- neutropenia
- dose
- νευο
- pegfilgrastim
- treatment
- Prior art date
Links
- 208000004235 neutropenia Diseases 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 title claims abstract description 55
- 208000002633 Febrile Neutropenia Diseases 0.000 title claims abstract description 44
- 201000002364 leukopenia Diseases 0.000 title claims abstract description 20
- 231100001022 leukopenia Toxicity 0.000 title claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 18
- 230000003247 decreasing effect Effects 0.000 title claims abstract description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 33
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 33
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims abstract description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 168
- 102000009027 Albumins Human genes 0.000 claims description 151
- 108010088751 Albumins Proteins 0.000 claims description 150
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 120
- 210000000440 neutrophil Anatomy 0.000 claims description 84
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 67
- 229960003668 docetaxel Drugs 0.000 claims description 66
- 229960004679 doxorubicin Drugs 0.000 claims description 60
- 241000699670 Mus sp. Species 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 48
- 229940079593 drug Drugs 0.000 claims description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 241000282693 Cercopithecidae Species 0.000 claims description 38
- 238000011084 recovery Methods 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 29
- 230000003039 myelosuppressive effect Effects 0.000 claims description 28
- 230000001154 acute effect Effects 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 210000003714 granulocyte Anatomy 0.000 claims description 24
- 230000005847 immunogenicity Effects 0.000 claims description 23
- 229940041181 antineoplastic drug Drugs 0.000 claims description 22
- 231100000673 dose–response relationship Toxicity 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 21
- 210000000265 leukocyte Anatomy 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 230000007423 decrease Effects 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000011160 research Methods 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 230000002489 hematologic effect Effects 0.000 claims description 14
- 239000000902 placebo Substances 0.000 claims description 14
- 229940068196 placebo Drugs 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 210000001185 bone marrow Anatomy 0.000 claims description 10
- 230000003472 neutralizing effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 229940068968 polysorbate 80 Drugs 0.000 claims description 9
- 206010065553 Bone marrow failure Diseases 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 230000002776 aggregation Effects 0.000 claims description 8
- 238000004220 aggregation Methods 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 210000000952 spleen Anatomy 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 239000008227 sterile water for injection Substances 0.000 claims description 6
- 229940104230 thymidine Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 206010033661 Pancytopenia Diseases 0.000 claims description 5
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 claims description 5
- 208000024389 cytopenia Diseases 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108700012359 toxins Proteins 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 201000010000 Agranulocytosis Diseases 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000004918 Cartilage-hair hypoplasia Diseases 0.000 claims description 4
- 206010062759 Congenital dyskeratosis Diseases 0.000 claims description 4
- 208000000280 Cyclic neutropenia Diseases 0.000 claims description 4
- 206010016880 Folate deficiency Diseases 0.000 claims description 4
- 229920002527 Glycogen Polymers 0.000 claims description 4
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims description 4
- 206010051645 Idiopathic neutropenia Diseases 0.000 claims description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010041660 Splenomegaly Diseases 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229940096919 glycogen Drugs 0.000 claims description 4
- 238000001631 haemodialysis Methods 0.000 claims description 4
- 230000000322 hemodialysis Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 206010024378 leukocytosis Diseases 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 201000006681 severe congenital neutropenia Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 229940074410 trehalose Drugs 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 208000037843 metastatic solid tumor Diseases 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 150000003278 haem Chemical class 0.000 claims description 2
- 238000011835 investigation Methods 0.000 claims description 2
- 230000002110 toxicologic effect Effects 0.000 claims description 2
- 231100000723 toxicological property Toxicity 0.000 claims description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 3
- 239000012907 medicinal substance Substances 0.000 claims 3
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 claims 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 claims 2
- 230000003749 cleanliness Effects 0.000 claims 2
- 239000002577 cryoprotective agent Substances 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 2
- 150000004683 dihydrates Chemical class 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 238000001471 micro-filtration Methods 0.000 claims 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 238000000108 ultra-filtration Methods 0.000 claims 2
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 241000951471 Citrus junos Species 0.000 claims 1
- 201000009084 Dysgammaglobulinemia Diseases 0.000 claims 1
- 101000984584 Homo sapiens Ribosome biogenesis protein BOP1 Proteins 0.000 claims 1
- 101000724404 Homo sapiens Saccharopine dehydrogenase Proteins 0.000 claims 1
- 241000283923 Marmota monax Species 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 102100027055 Ribosome biogenesis protein BOP1 Human genes 0.000 claims 1
- 108091006625 SLC10A6 Proteins 0.000 claims 1
- 102100028294 Saccharopine dehydrogenase Human genes 0.000 claims 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 239000001164 aluminium sulphate Substances 0.000 claims 1
- 231100001025 bone marrow hyperplasia Toxicity 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000011097 chromatography purification Methods 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000011118 depth filtration Methods 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 108010044644 pegfilgrastim Proteins 0.000 description 180
- 229960001373 pegfilgrastim Drugs 0.000 description 180
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 177
- 108090000623 proteins and genes Proteins 0.000 description 119
- 235000018102 proteins Nutrition 0.000 description 118
- 102000004169 proteins and genes Human genes 0.000 description 118
- 108090000765 processed proteins & peptides Proteins 0.000 description 103
- 102000004196 processed proteins & peptides Human genes 0.000 description 100
- 229920001184 polypeptide Polymers 0.000 description 98
- 108020001507 fusion proteins Proteins 0.000 description 88
- 102000037865 fusion proteins Human genes 0.000 description 88
- 238000002512 chemotherapy Methods 0.000 description 86
- 230000000694 effects Effects 0.000 description 77
- 108010029961 Filgrastim Proteins 0.000 description 72
- 108091033319 polynucleotide Proteins 0.000 description 50
- 102000040430 polynucleotide Human genes 0.000 description 50
- 239000002157 polynucleotide Substances 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 46
- 239000012634 fragment Substances 0.000 description 44
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 36
- 229960004177 filgrastim Drugs 0.000 description 36
- 229940029345 neupogen Drugs 0.000 description 36
- 238000012217 deletion Methods 0.000 description 34
- 230000037430 deletion Effects 0.000 description 34
- 230000002411 adverse Effects 0.000 description 30
- 238000001990 intravenous administration Methods 0.000 description 26
- 210000005259 peripheral blood Anatomy 0.000 description 25
- 239000011886 peripheral blood Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 230000002281 colonystimulating effect Effects 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 102000007562 Serum Albumin Human genes 0.000 description 18
- 108010071390 Serum Albumin Proteins 0.000 description 18
- 238000009739 binding Methods 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- 125000000539 amino acid group Chemical group 0.000 description 17
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 230000003285 pharmacodynamic effect Effects 0.000 description 15
- 230000000144 pharmacologic effect Effects 0.000 description 15
- 206010020751 Hypersensitivity Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000000973 chemotherapeutic effect Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 229960004316 cisplatin Drugs 0.000 description 11
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 229960005420 etoposide Drugs 0.000 description 10
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241000282567 Macaca fascicularis Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000003651 basophil Anatomy 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 8
- 210000003979 eosinophil Anatomy 0.000 description 8
- 230000005714 functional activity Effects 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000009104 chemotherapy regimen Methods 0.000 description 7
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 208000003265 stomatitis Diseases 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 206010006002 Bone pain Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 6
- 229940045799 anthracyclines and related substance Drugs 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282553 Macaca Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 229960003901 dacarbazine Drugs 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000002045 lasting effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000002001 anti-metastasis Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000009101 premedication Methods 0.000 description 4
- 238000009094 second-line therapy Methods 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960003048 vinblastine Drugs 0.000 description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 206010015866 Extravasation Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010029379 Neutrophilia Diseases 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010038111 Recurrent cancer Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 108010080374 albuferon Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 231100000226 haematotoxicity Toxicity 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940126602 investigational medicinal product Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000000282 nail Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229940063683 taxotere Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 206010013886 Dysaesthesia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 101100187345 Xenopus laevis noto gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical class 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000031066 hyperpigmentation of the skin Diseases 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 229960004635 mesna Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001605775 Epidemas Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100014660 Rattus norvegicus Gimap8 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ARYLBQOVLQRPOG-UHFFFAOYSA-L disodium;4-[4-[4-(3-carboxylatopropanoylamino)phenyl]sulfonylanilino]-4-oxobutanoate Chemical compound [Na+].[Na+].C1=CC(NC(=O)CCC(=O)[O-])=CC=C1S(=O)(=O)C1=CC=C(NC(=O)CCC([O-])=O)C=C1 ARYLBQOVLQRPOG-UHFFFAOYSA-L 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- GBPZYMBDOBODNK-SFTDATJTSA-N ethyl (2s)-2-[[(2s)-2-acetamido-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylpentanoate Chemical compound CCOC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(N(CCCl)CCCl)C=C1 GBPZYMBDOBODNK-SFTDATJTSA-N 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000019244 fetal lower urinary tract obstruction Diseases 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012495 forced degradation study Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000000788 granulopoietic effect Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000052 myelotoxic Toxicity 0.000 description 1
- 230000002556 myelotoxic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 241000061450 x Ascocenda Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14544009P | 2009-01-16 | 2009-01-16 | |
| US14543609P | 2009-01-16 | 2009-01-16 | |
| PCT/US2010/021241 WO2010083439A2 (en) | 2009-01-16 | 2010-01-15 | Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201190080A1 EA201190080A1 (ru) | 2014-03-31 |
| EA023344B1 true EA023344B1 (ru) | 2016-05-31 |
Family
ID=42260335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201190080A EA023344B1 (ru) | 2009-01-16 | 2010-01-15 | Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией |
| EA201190079A EA201190079A1 (ru) | 2009-01-16 | 2010-01-15 | Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201190079A EA201190079A1 (ru) | 2009-01-16 | 2010-01-15 | Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20100227818A1 (enExample) |
| EP (2) | EP2387420A2 (enExample) |
| JP (2) | JP2012515222A (enExample) |
| KR (2) | KR20110132326A (enExample) |
| CN (2) | CN102395379B (enExample) |
| AU (2) | AU2010204547B2 (enExample) |
| BR (2) | BRPI1005159A2 (enExample) |
| CA (2) | CA2749802C (enExample) |
| EA (2) | EA023344B1 (enExample) |
| IL (2) | IL214051A0 (enExample) |
| MX (2) | MX2011007583A (enExample) |
| NZ (2) | NZ594055A (enExample) |
| SG (3) | SG172941A1 (enExample) |
| UA (2) | UA103221C2 (enExample) |
| WO (2) | WO2010083434A2 (enExample) |
| ZA (1) | ZA201105171B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187786A1 (en) * | 2017-04-07 | 2018-10-11 | La Jolla Institute For Allergy And Immunology | Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2387420A2 (en) * | 2009-01-16 | 2011-11-23 | Teva Pharmaceutical Industries Limited | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
| EP2384759A1 (en) | 2010-05-06 | 2011-11-09 | Suomen Punainen Risti Veripalvelu | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells |
| JP5981423B2 (ja) * | 2010-06-07 | 2016-08-31 | アムジエン・インコーポレーテツド | 薬物送達デバイス |
| CN102628869B (zh) * | 2012-04-19 | 2014-04-02 | 上海蓝怡科技有限公司 | 提高甲胎蛋白抗体冻干稳定性的制剂 |
| US9409662B2 (en) | 2013-01-15 | 2016-08-09 | Teva Pharmaceutical Industries, Ltd. | Formulations of albu-BChE, preparation and uses thereof |
| WO2014147489A2 (en) | 2013-03-15 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients |
| MA40904A (fr) * | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
| RU2736045C2 (ru) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения рака, ассоциированного с мутацией ras |
| BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
| CA2991059C (en) | 2015-07-13 | 2024-01-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin monohydrate polymorphs |
| ES2852002T3 (es) * | 2015-07-30 | 2021-09-10 | Endor Tech S L | Factor estimulante de colonias para su uso en el tratamiento del cáncer de páncreas o de colon |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| US11229642B2 (en) | 2016-06-06 | 2022-01-25 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| CN106222221A (zh) * | 2016-08-05 | 2016-12-14 | 山东科兴生物制品有限公司 | 制备重组人粒细胞刺激因子原液的纯化方法 |
| WO2018096534A1 (en) | 2016-11-22 | 2018-05-31 | Sorrel Medical Ltd. | Apparatus for delivering a therapeutic substance |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MY201811A (en) | 2017-02-01 | 2024-03-19 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| CN109420159A (zh) * | 2017-08-23 | 2019-03-05 | 江苏泰康生物医药有限公司 | 一种重组蛋白药物的新型稳定制剂 |
| AU2019212118A1 (en) | 2018-01-24 | 2020-09-03 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CN112105363A (zh) * | 2018-02-01 | 2020-12-18 | 大连万春布林医药有限公司 | 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法 |
| US11583633B2 (en) | 2018-04-03 | 2023-02-21 | Amgen Inc. | Systems and methods for delayed drug delivery |
| EP3632487B1 (en) | 2018-10-05 | 2024-06-12 | LTS Device Technologies Ltd | Triggering sequence |
| CN111383745A (zh) * | 2018-12-29 | 2020-07-07 | 医渡云（北京）技术有限公司 | 计算机数据处理方法、装置、存储介质及设备 |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) * | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| CN112316120A (zh) * | 2019-08-05 | 2021-02-05 | 天津派格生物技术有限公司 | 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法 |
| WO2021112654A1 (en) * | 2019-12-05 | 2021-06-10 | Hanmi Pharm. Co., Ltd. | Methods of treating chemotherapy or radiotherapy induced neutropenia |
| KR102485892B1 (ko) * | 2020-04-09 | 2023-01-09 | 주식회사 에이프릴바이오 | 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도 |
| CN111751552B (zh) * | 2020-06-18 | 2022-09-16 | 广州市伊川生物科技有限公司 | 一种缺血修饰白蛋白测定试剂盒及其使用方法 |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| US11723955B1 (en) * | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015199A1 (fr) * | 1992-01-31 | 1993-08-05 | Rhone-Poulenc Rorer S.A. | Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant |
| US5665863A (en) * | 1992-01-31 | 1997-09-09 | Rhone-Poulenc Rorer S.A. | Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them |
| US20030118612A1 (en) * | 2000-01-10 | 2003-06-26 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US20080153751A1 (en) * | 2001-12-21 | 2008-06-26 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052712T3 (es) | 1987-04-09 | 1994-07-16 | Delta Biotechnology Ltd | Vector de levadura. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| DE19549232C2 (de) * | 1995-12-20 | 1998-05-20 | Boehringer Mannheim Gmbh | Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern |
| US7321023B2 (en) * | 1997-11-07 | 2008-01-22 | Incyte Corporation | SP16 protein |
| JP3895109B2 (ja) * | 1998-03-06 | 2007-03-22 | 中外製薬株式会社 | 蛋白非添加製剤 |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| EP1276856A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| AU2002302814A1 (en) * | 2001-06-08 | 2002-12-23 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| CN1241946C (zh) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| US20070041987A1 (en) * | 2003-03-19 | 2007-02-22 | Daniel Carter | Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development |
| US6972332B1 (en) * | 2004-05-20 | 2005-12-06 | Acura Pharmaceuticals, Inc. | Process for the production of opiates |
| MX2008001865A (es) * | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| CA2584927C (en) * | 2006-04-13 | 2011-02-08 | Wix Filtration Corp. | A body for actuating a standpipe of a replaceable filter element |
| JP2008146587A (ja) * | 2006-12-13 | 2008-06-26 | Sony Corp | 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体 |
| EP2387420A2 (en) | 2009-01-16 | 2011-11-23 | Teva Pharmaceutical Industries Limited | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
-
2010
- 2010-01-15 EP EP10701082A patent/EP2387420A2/en not_active Withdrawn
- 2010-01-15 UA UAA201109963A patent/UA103221C2/uk unknown
- 2010-01-15 EA EA201190080A patent/EA023344B1/ru not_active IP Right Cessation
- 2010-01-15 SG SG2011050366A patent/SG172941A1/en unknown
- 2010-01-15 WO PCT/US2010/021235 patent/WO2010083434A2/en not_active Ceased
- 2010-01-15 MX MX2011007583A patent/MX2011007583A/es active IP Right Grant
- 2010-01-15 JP JP2011546399A patent/JP2012515222A/ja active Pending
- 2010-01-15 KR KR1020117018153A patent/KR20110132326A/ko not_active Ceased
- 2010-01-15 SG SG2014003073A patent/SG196821A1/en unknown
- 2010-01-15 AU AU2010204547A patent/AU2010204547B2/en not_active Ceased
- 2010-01-15 CA CA2749802A patent/CA2749802C/en not_active Expired - Fee Related
- 2010-01-15 KR KR1020117018162A patent/KR20110132327A/ko not_active Ceased
- 2010-01-15 JP JP2011546396A patent/JP5753095B2/ja not_active Expired - Fee Related
- 2010-01-15 CN CN201080012749.8A patent/CN102395379B/zh not_active Expired - Fee Related
- 2010-01-15 MX MX2011007582A patent/MX2011007582A/es active IP Right Grant
- 2010-01-15 US US12/688,754 patent/US20100227818A1/en not_active Abandoned
- 2010-01-15 EA EA201190079A patent/EA201190079A1/ru unknown
- 2010-01-15 NZ NZ594055A patent/NZ594055A/xx not_active IP Right Cessation
- 2010-01-15 EP EP10700685A patent/EP2387419A2/en not_active Withdrawn
- 2010-01-15 US US12/688,655 patent/US8323634B2/en not_active Expired - Fee Related
- 2010-01-15 BR BRPI1005159A patent/BRPI1005159A2/pt not_active IP Right Cessation
- 2010-01-15 WO PCT/US2010/021241 patent/WO2010083439A2/en not_active Ceased
- 2010-01-15 UA UAA201109961A patent/UA105201C2/uk unknown
- 2010-01-15 CA CA2749786A patent/CA2749786A1/en not_active Abandoned
- 2010-01-15 SG SG2011050358A patent/SG172940A1/en unknown
- 2010-01-15 AU AU2010204552A patent/AU2010204552B2/en not_active Ceased
- 2010-01-15 NZ NZ594056A patent/NZ594056A/xx not_active IP Right Cessation
- 2010-01-15 CN CN2010800127233A patent/CN102378635A/zh active Pending
- 2010-01-15 BR BRPI1004940A patent/BRPI1004940A2/pt not_active IP Right Cessation
-
2011
- 2011-07-12 IL IL214051A patent/IL214051A0/en unknown
- 2011-07-12 IL IL214052A patent/IL214052A0/en unknown
- 2011-07-13 ZA ZA2011/05171A patent/ZA201105171B/en unknown
-
2012
- 2012-10-25 US US13/660,915 patent/US8993519B2/en not_active Expired - Fee Related
-
2014
- 2014-12-18 US US14/574,553 patent/US20150202268A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015199A1 (fr) * | 1992-01-31 | 1993-08-05 | Rhone-Poulenc Rorer S.A. | Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant |
| US5665863A (en) * | 1992-01-31 | 1997-09-09 | Rhone-Poulenc Rorer S.A. | Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them |
| US20030118612A1 (en) * | 2000-01-10 | 2003-06-26 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US20080153751A1 (en) * | 2001-12-21 | 2008-06-26 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
Non-Patent Citations (2)
| Title |
|---|
| Dave Mead: "Novozymes Biopharma-Rethinking Tomorrow", October 2008 (2008-10), XP002589546, Retrieved from the Internet:URL:http://www.biopharma.novozymes.com/Admin/Public/DWSDownload.aspx?File=%2FFiles%2FFiler%2FPresentations%2FBPE08_DaveMead_Oct08.pdf [retrieved on 2010-06-29], Slides 14, 16 * |
| HALPERN WENDY ET AL.: "Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice andmonkeys." PHARMACEUTICAL RESEARCH NOV 2002 LNKD-PUBMED:12458679, vol. 19, no. 11, November 2002 (2002-11), pages 1720-1729, XP002589130, ISSN: 0724-8741, the whole document * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187786A1 (en) * | 2017-04-07 | 2018-10-11 | La Jolla Institute For Allergy And Immunology | Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023344B1 (ru) | Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией | |
| US11358995B2 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP2017519009A (ja) | 製剤化された受容体ポリペプチドおよび関連する方法 | |
| ES2950570T3 (es) | Composición farmacéutica del complejo de proteína il-15 y usos de la misma | |
| UA128757C2 (uk) | Антитіла, які містять тільки важкі ланцюги, що зв'язуються з cd22 | |
| KR20210088548A (ko) | 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료 | |
| JP2015518835A (ja) | 癌幹細胞を標的とした癌ワクチン | |
| Deepak et al. | Placental drug delivery to treat pre‐eclampsia and fetal growth restriction | |
| US20210100877A1 (en) | Use of il-22 in treating necrotizing enterocolitis | |
| US20160152710A1 (en) | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake | |
| US11560412B2 (en) | Compositions comprising GRIM-19 therapeutics and methods of use | |
| US10967047B2 (en) | Mitochondrial antiviral-signaling (MAVS) polypeptides and detection and use thereof | |
| BR112020024683A2 (pt) | Métodos de uso de cd24 para a prevenção e tratamento de doença do enxerto versus hospedeiro e mucosite | |
| Kijanka et al. | Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4+ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants | |
| US20230167162A1 (en) | Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa | |
| US20140271538A1 (en) | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients | |
| JPWO2020092523A5 (enExample) | ||
| US20250295587A1 (en) | Complex lipid nanoparticles encapsulating polypeptides and uses thereof | |
| AU2014202190B2 (en) | New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein | |
| BR112017001789B1 (pt) | Polipeptídeos, dímero, método de produção dos mesmos, composição farmacêutica, uso dos mesmos e recipiente estéril para tratamento de distúrbios metabólicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |